Navigation Links
Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration
Date:12/14/2009

is not successful in achieving a sale of assets, restructuring, financing or any combination thereof, the Company will have to curtail or cease operations, liquidate its assets or file for bankruptcy. The Company expects to make decisions in the near future.

For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion being unsuccessful in achieving its strategic alternatives, including any combination of a restructuring of the Company and its debt, a sale of the Company or its assets, and raising new capital, in which case it will curtail or cease operations, liquidate its assets or file for bankruptcy, the FDA requiring Vion to conduct a new randomized trial for Onrigin(TM) (laromustine) Injection prior to regulatory approval, Vion's potential inability to obtain regulatory approval for its products, particularly Onrigin(TM), delays in the regulatory approval process, particularly for Onrigin(TM), delays or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not confirmed by safety and efficacy results in later or final clinical trials, the need for additional research and testing, including the need for a randomized trial of Onrigin(TM) prior to regulatory approval, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, an
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014  Celsion Corporation (NASDAQ: ... today that the Company will ring the NASDAQ Stock Market ... New York, NY . ... of the Celsion and EGEN management teams will participate in ... pm ET.  A live webcast will be available at ...
(Date:7/14/2014)... Minn. , July 14, 2014  Today, ATS ... announced that it acquired the assets of MicroTest Labs, ... The acquisition of MTL is the first step in ... chemistry laboratory services platform to support the medical device ... known as Accuratus Lab Services , a name ...
(Date:7/14/2014)... 2014  Diomics, Inc., provider of X-Swab™, a ... United States Patent and Trademark Office has issued ... biologic sample collection materials, devices made from them, ... diagnostics. The primary method of ... of DNA from a number of commercially-available swabs ...
Breaking Medicine Technology:Celsion Corporation to Ring the NASDAQ Stock Market Closing Bell on July 16, 2014 2Celsion Corporation to Ring the NASDAQ Stock Market Closing Bell on July 16, 2014 3ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 2ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 3Diomics Announces Issuance Of U.S. Patents For Novel Biologic Sample DNA Collection Materials For Use In Forensics And Diagnostics 2
... 31, 2012 /PRNewswire-iReach/ -- Global BioClinical (GBC) ... to the corporate team. Ms. Maas has joined GBC ... a Clinical Research Manager at Epigenomics, Inc., Ms. Maas ... responsible for a variety of clinical research studies, international ...
... According to a new market report published by ... Market (Surgical Sutures, Surgical Hand Instruments and Electrosurgical Devices) ... Analysis (2010 - 2017) "; the global surgical equipment ... is forecasted to reach USD 7.5 billion in 2017 ...
Cached Medicine Technology:Global BioClinical Welcomes Jennifer Maas as Senior Consultant 2Surgical Equipment Market (Surgical Sutures, Surgical Hand Instruments and Electrosurgical Devices) Estimated to Reach USD 7.5 Billion Globally in 2017: Transparency Market Research 2Surgical Equipment Market (Surgical Sutures, Surgical Hand Instruments and Electrosurgical Devices) Estimated to Reach USD 7.5 Billion Globally in 2017: Transparency Market Research 3Surgical Equipment Market (Surgical Sutures, Surgical Hand Instruments and Electrosurgical Devices) Estimated to Reach USD 7.5 Billion Globally in 2017: Transparency Market Research 4Surgical Equipment Market (Surgical Sutures, Surgical Hand Instruments and Electrosurgical Devices) Estimated to Reach USD 7.5 Billion Globally in 2017: Transparency Market Research 5
(Date:7/14/2014)... SUNDAY, July 13, 2014 (HealthDay News) -- Eye tests ... stages of Alzheimer,s disease, two new studies suggest. ... used a certain eye test found a significant association ... the eye and levels of the plaques in the ... Alzheimer,s disease. This type of eye test could ...
(Date:7/14/2014)... HealthDay Reporter MONDAY, July 14, 2014 ... may have bigger brains and sharper thinking skills than their ... connection between playing games such as puzzles, crosswords, cards and ... 60s. Researchers found that people who played those games ... memory and other mental functions. And, based on MRI scans, ...
(Date:7/14/2014)... Many people are unhappy with their ... to reduce a “double chin.” A new product ... to go under the knife. Jawflex is a double ... therefore tightening the skin in that area and reducing ... used for facial exercise, double chin elimination and sagging ...
(Date:7/14/2014)... July 14, 2014 Many diet plans often ... study by the School of Public Health at the University ... had a near-zero effect on weight loss. Now experts are ... with some form of portion control to trigger ... monitoring portions and controlling how much is consumed, simply by ...
(Date:7/14/2014)... Sometimes, thinking “inside the box” can ... its first product release, Joyboxx™ - The world’s only ... , Inventor and CEO, Deborah Semer began designing ... storage solution for their ‘toys’ after she realized no ... industry. , Semer met 30-year industry veteran Phyllis Heppenstall, ...
Breaking Medicine News(10 mins):Health News:Eye Tests Might Help ID Alzheimer's, Studies Suggest 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 3Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 3Health News:Passionate Playground launches Joyboxx 2Health News:Passionate Playground launches Joyboxx 3
... Win Patient Safety Protections, OAKLAND, Calif., ... University of California medical centers throughout the ... majority, the California Nurses Association,announced today. The ... as resolving long-standing issues of pension and ...
... serious trauma live, often with little visible damage, surgeons say ... of war in Iraq, there,s some relatively good medical ... are now surviving injuries that would have been fatal in ... The Journal of Craniofacial Surgery , the surgical and treatment ...
... Mich., March 24 Perrigo Company,(Nasdaq: PRGO ... CEO Joseph,C. Papa will present at the 12th ... March 25, at 2:05 p.m. (ET) at the,Grand ... Company is a leading global healthcare supplier that ...
... Fitness,Corporation (OTC Bulletin Board: HFIT) today announced that ... repurchase up to $2.5 million of the,company,s outstanding ... shares on the open market in amounts and ... with Securities and Exchange,Commission Rule 10b-18 and other ...
... urged to discuss risk factors with their doctors, ... long been known that,psoriasis, a chronic skin condition ... bleed, can have a significant negative impact on ... finding that,psoriasis, especially severe psoriasis, is linked with ...
... International,Corporation (Nasdaq: PRXL ) announced today it will ... Conference. James Winschel, Senior Vice,President and Chief Financial Officer ... a.m. ET on Thursday, March 27, 2008., A ... the,"Investor Relations Webcasts" section of PAREXEL,s web site at, ...
Cached Medicine News:Health News:UC RNs Overwhelmingly Approve New Contract 2Health News:UC RNs Overwhelmingly Approve New Contract 3Health News:Innovative Care Is Helping Iraq War's Injured Survive 2Health News:Innovative Care Is Helping Iraq War's Injured Survive 3Health News:Health Fitness Announces $2.5 Million Stock Repurchase Plan 2Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 2Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 3Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 4Health News:PAREXEL International to Present at Bank of America 2008 Smid Cap Conference 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: